1 Of these participants, 819 (84.
8%)
were available for primary outcome analysis at 6-month follow
2 Ninety manual
annotations were available for model training and validation.
3 Data were available for 100 subjects with severe asthma (median ag
4 Data were available for 214 patients for the primary analysis; eme
5 Data were available for 305 pwMND (mean age at diagnosis=62.26 yea
6 Clinical
data were available for analysis from 38 patients, including 12 wi
7 In contrast,
data were available for 79% of eligible articles, highlighting tha
8 Complete outcome and covariate
data were available for 4,428 and 4,369 participants at ages 14 an
9 Ct
data were available for 106 (71%) of 150 enrolled index patients.
10 with Defibrotide for VOD/SOS diagnosis, where detailed
data were available for final analysis.
11 Fracture
data were available for 9802 of the 9803 participants.
12 Of the 804 PACG patients, genotyping
data were available for 768 individuals and included 436 with mild
13 Structural magnetic resonance imaging
data were available for 250 participants.
14 There was unmeasured confounding and no laboratory
data were available for the majority of patients, and molecule-spe
15 Methods:
Data were available for 10 patients with neuroendocrine tumors tre
16 Primary outcome
data were available for 1692 infants (92.8%).
17 Serial
data were available for analysis from 70 patients (LLL <0.5 mm: n=
18 Follow-up
data were available for 1014 patients who were included in the int
19 4-month follow-up
data were available for 406 (64%) participants, 25 were lost to fo
20 Complete follow-up
data were available for 99.2% of the neonates.
21 Vaccination
data were available for 91 (83%) cases; 51 (56%) had 2 RV1 doses a
22 Of 1046 eligible eyes, 10-year
data were available for 293 (28%), which were included in the anal
23 following: (i) large scale differential binding sites (
DBS)
were available for only H3K4me3 in the susceptible cultivar,
24 Forty-five
ECGs were available for corrected QT interval (QTc) measurement, a
25 Research and development
expenditures were available for 63 (18%) products, developed by 47 differe
26 After inclusion/exclusion criteria, 316
eyes were available for analysis; 131 eyes had MMC delivered via s
27 uct use, antibiotic administration, and signs of
infection)
were available for 98.7% randomized to the probiotic group an
28 Outcome data at 1 year after spinal
injury were available for 1031 patients (66.6%).
29 atients originally evaluated using the DeltaSUV(max)
method were available for post hoc assessment of the Deauville score
30 le range, 21 to 27) in the control group; data on
mortality were available for 99.9% of patients in the study.
31 Data on the primary
outcome were available for 206 women (81%).
32 Live birth
outcomes were available for all couples, and 1629 men (69%) had semen
33 9147 patients were included, of whom seizure
outcomes were available for 8191 (89.5%) participants at 2 years, and
34 Data from 136
participants were available for the intention-to-treat analysis of the pri
35 ) and by weight categories: <5, 5-10, >10 kg; 1033
patients were available for analysis.
36 Samples from 135
patients were available for analysis.
37 Data from 89 evaluable
patients were available for the purpose of analysis comprising an init
38 Fifty-five
patients were available for statistical analysis (test group, n = 28;
39 Five-year
photographs were available for 615/862 (71%) eligible patients.
40 779 subjects and 1,192,414 single-nucleotide
polymorphisms were available for PRS-analyses.
41 Breast milk
samples were available for 31 LOD cases (8 serotype Ia and 23 serotyp
42 Biannual
series were available for 422 eyes of 214 participants.
43 d pooled estimates for each lag when at least three
studies were available for a specific lag.
44 Dietary
surveys were available for analysis from 614 (77%), and 561 (71%) par
45 Additional pathological comparisons
that were available for a subset in ADNI suggested that subtypes s
46 cohort wherein whole body autopsy reports and brain
tissue were available for interrogation was established.
47 A total of 29
VTs were available for comparison.
48 A total of 10 patients
who were available for tryptase genotyping were all confirmed to
49 eta PET, tau PET, and aHCV measurements at 0.6 to 4.1
years were available for 35% to 63% of the sample.
50 s, longitudinal measures (with a mean follow-up of 6
years)
were available for 242 mutation carriers and 262 non-carriers